Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-111992
Filing Date
2025-08-28
Accepted
2025-08-28 16:36:16
Documents
1
Period of Report
2025-08-26

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 4547
  Complete submission text file 0000950170-25-111992.txt   6148
Mailing Address C/O BRIDGEBIO ONCOLOGY THERAPEUTICS, INC 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address
Wallace Eli M. (Reporting) CIK: 0001776352 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41955 | Film No.: 251274112

Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Issuer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)